Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.

Original languageEnglish
Pages (from-to)885-892
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

S 20098
Pharmacokinetics
Anxiety Disorders
Therapeutics
Molecules
Expert Testimony
Alcoholism
Psychiatry
Half-Life
Publications
Comorbidity
Language
Anxiety
Odds Ratio
Alcohols
Databases

Keywords

  • Agomelatine
  • Generalised anxiety disorder
  • Pharmacokinetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

@article{ae46afe3cc55447d9497da82e3703711,
title = "Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder",
abstract = "Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.",
keywords = "Agomelatine, Generalised anxiety disorder, Pharmacokinetics",
author = "Massimiliano Buoli and Mauri, {Massimo Carlo} and Altamura, {Alfredo Carlo}",
year = "2014",
doi = "10.1517/17425255.2014.907794",
language = "English",
volume = "10",
pages = "885--892",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

AU - Buoli, Massimiliano

AU - Mauri, Massimo Carlo

AU - Altamura, Alfredo Carlo

PY - 2014

Y1 - 2014

N2 - Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.

AB - Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.

KW - Agomelatine

KW - Generalised anxiety disorder

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84901052733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901052733&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.907794

DO - 10.1517/17425255.2014.907794

M3 - Article

VL - 10

SP - 885

EP - 892

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -